Detection of drug-induced proarrhythmia: Balancing preclinical and clinical studies

Heart Rhythm

Volumn 2, Issue 7, 2005, Pages 773-776

  Malik, Marek ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CISAPRIDE; FEXOFENADINE; ION CHANNEL; MOXIFLOXACIN; QUINIDINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

AFTERHYPERPOLARIZATION; BRUGADA SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; DRUG INDUSTRY; EDITORIAL; ELECTROCARDIOGRAM; HEART ELECTROPHYSIOLOGY; HEART MUSCLE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; T WAVE; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; HUMANS; LONG QT SYNDROME; MODELS, CARDIOVASCULAR; PAPILLARY MUSCLES; POTASSIUM CHANNELS; TORSADES DE POINTES;

EID: 21344434324     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2005.04.018     Document Type: Editorial

References (21)

1. International Conference on harmonisation. The clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Draft available at http://www.fda.gov/cder/ calendar/meeting/qt4jam.pdf Accessed May 2005.
2. R.R. Fenichel M. Malik C. Antzelevitch M. Sanguinetti D.M. Roden S.G. Priori J.N. Ruskin R.J. Lipicky L.R. Cantilena Drug-induced torsades de pointes and implications for drug development J Cardiovasc Electrophysiol 15 2004 475-495
3. D.M. Roden R.L. Woosley R.K. Primm Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care Am Heart J 111 1986 1088-1093
4. G.N. Kay V.J. Plumb J.G. Arciniegas R.W. Henthorn A.L. Waldo Torsade de pointes: The long-short initiating sequence and other clinical features: observations in 32 patients J Am Coll Cardiol 2 1983 806-817
5. Y.M. Pinto I.C. van Gelder M. Heeringa H.J. Crijns QT lengthening and life-threatening arrhythmias associated with fexofenadine Lancet 353 1999 980
6. P.K. Honig D.C. Wortham K. Zamani D.P. Conner J.C. Mullin L.R. Cantilena Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences JAMA 269 1993 1513-1518
7. A.M. Walker P. Szneke L.B. Weatherby L.W. Dicker L.L. Lanza J.E. Loughlin C.L. Yee N.A. Dreyer The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada Am J Med 107 1999 356-362
8. J.L. Miller FDA, Janssen bolster cardiac risk warnings for cisapride Am J Health Syst Pharm 57 2000 414
9. M.E. Anderson A. Mazur T. Yang D.M. Roden Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics J Pharmacol Exp Ther 296 2001 806-810
10. G.J. Noel J. Natarajan S. Chien T.L. Hunt D.B. Goodman R. Abels Effects of three fluoroquinolones on QT interval in healthy adults after single doses Clin Pharmacol Ther 73 2003 292-303
11. R.R. Shah L.M. Hondeghem Refining detection of drug-induced proarrhythmia: QT interval and TRIaD Heart Rhythm 2 2005 758-772
12. R. Matthews Of mice, men and medical concern Financial Times March 4, 2005 p. 11
13. T. Yang D. Snyders D.M. Roden Drug block of I(kr): Model systems and relevance to human arrhythmias J Cardiovasc Pharmacol 38 2001 737-744
14. A.A. Paul H.J. Witchel J.C. Hancox Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide Biochem Biophys Res Commun 280 2001 1243-1250
15. W.J. Crumb Jr Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions J Pharmacol Exp Ther 292 2000 261-264
16. M. Taglialatela A. Pannaccione P. Castaldo G. Giorgio Z. Zhou C.T. January A. Genovese G. Marone L. Annunziato Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines Mol Pharmacol 54 1998 113-121
17. Malik M. Drug-induced QT interval prolongation: Why is it of concern? Available at http://www.fda.gov/ohrms/dockets/ac/03/slides/ 4000S1_05_Malik_files/frame.htm. Accessed May 2005.
18. C. Antzelevitch L. Belardinelli A.C. Zygmunt A. Burashnikov J.M. Di Diego J.M. Fish J.M. Cordeiro G. Thomas Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 2004 904-910
19. J.C. Shryock Y. Song L. Wu H. Fraser L. Belardinelli A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies J Electrocardiol 37 Suppl 2004 34-39
20. J. Nemec J.B. Hejlik W.K. Shen M.J. Ackerman Catecholamine-induced T-wave lability in congenital long QT syndrome: A novel phenomenon associated with syncope and cardiac arrest Mayo Clin Proc 78 2003 40-50
21. P. Smetana E. Pueyo K. Hnatkova V. Batchvarov A.J. Camm M. Malik Effect of amiodarone on the descending limb of the T wave Am J Cardiol 92 2003 742-746